Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Investor Presentation (February 2018)
23 slides from Sanuwave Health's investor presentation, Feb 14, 2018
Slide 1: SANUWAVE: Healing today. Curing tomorrow.
SANUVAVE' Healing today. Curing tomorrow. Applying shockwave technology to repair and regenerate skin, musculoskeletal tissue, and vascular structures OTCQB: SNWV February 2018
Slide 2: Forward-Looking Statement Disclaimer
Forward-Looking Statement Disclaimer This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective.
Slide 3: SANUWAVE Health is an emerging shockwave technology company
SANUWAVE Health (SNWYV), Inc. is an emerging shockwave technology company focused on the development and commercialization of patented noninvasive, high-energy, acoustic shockwaves for the repair and regeneration of tissue, musculoskeletal and vascular structures. FDA permitted marketing of the derm
Slide 4: Investment Highlights & Recent Developments
Investment Highlights & Recent Developments = Accomplishments in 2017 « Received FDA De Novo decision to immediately market the dermaPACE system Brazil Joint Venture (NPV > $25Mn) Entered 7 new international markets Board of Directors expanded from 4 to 5 members Science advisory board expanded from
Slide 5: Investment Highlights & Recent Developments
Investment Highlights & Recent Developments = FDA clearance received December 28, 2017 * dermaPACE® as a Class II medical device for treatment of diabetic foot ulcers * Lower cost and non-invasive treatment. * dermaPACE® addresses a large and growing wound care market - $4B U.S. for DFU’s, $22B Worl
Slide 6: A Leader in Shockwave Technology
A Leader in Shockwave Technology Development and Commercialization « Patented, non-invasive devices for the repair and regeneration of: * Skin = Musculoskeletal tissue = Vascular structures = Devices activate biologic signaling and angiogenic responses, producing: = New vascularization = Microcircul
Slide 7: PACE — Total Addressable U.S. Market - $12B
PACE — Total Addressable U.S. Market - $12B Advanced Wound Care - Big dollar opportunity, even at 5% market share rdiac * Diabetic Foot Ulcer * Sports Medicine * Stem Cell * Scar Modulation * Blood Sterilization * Chronic Mixed Wounds * Tendon / Pain Proliferation * Reconstructive * Peripheral Arter
Slide 8: dermaPACE — Market Opportunity
dermaPACE — Market Opportunity U.S. Market Diabetic Foot Ulcers - $4B+ market size. 29 million people living with diabetes and 86 million pre-diabetics. 25% of diabetics will acquire a non- healing ulcer in their lifetime; ~3 million diabetic ulcers annually. Diabetic foot ulcers lead to over 73,000
Slide 9: dermaPACE - Treating Diabetic Foot Ulcers
dermaPACE - Treating Diabetic Foot Ulcers Treatment Advantages » Robust closure with extremely low recurrence rates Non-invasive, convenient, and safe Mechanism of action (MOA) allows : = Increased blood flow (perfusion) and improved vascularization (angiogenesis) = Restored oxygenation to ischemic
Slide 10: dermaPACE Commercial Plan for U.S.
dermaPACE Commercial Plan for U.S. «= SANUWAVE’s business model is a per procedure pricing model « Treatment parameters inserted by physician into the console « In most cases patients receive up to eight noninvasive procedures of 500 impulses, which take approximately 10 minutes each, dermaPACE bein
Slide 11: dermaPACE Commercial Plan for Other Markets
dermaPACE Commercial Plan for Other Markets «= SANUWAVE’s business model is a per procedure pricing model « RFID card readers are built into each generator box. Sell individual procedure kits which contain procedure specific protocol RFID cards that activate the device for treatment « In most cases
Slide 12: dermaPACE — Compelling Cost and Convenience
dermaPACE — Compelling Cost and Convenience The only treatment that causes major increase in vascularization required to close wounds dermaPACE offers: Advanced Modality Cost Comparison for DFU Treatment Y Non-invasive $16,000 treatment #15900 S000 $11,600 Y Lowest total treatment $12,000 cost $10,0
Slide 13: Growth Strategy
Growth Strategy Seek relationships with qualified partners and JV/licensing agreements = Address advanced wound care market - large and growing @ = Serve other medical markets; g Industrial orthopedics, plastic/cosmetic, Other Applications vascular/cardiac Medical @ Markets = Expand to non-medical i
Slide 14: Business Model Transformation
Business Model Transformation Transform from a product company to a provider of comprehensive value propositions and solutions that address the wound care patient pathway Current Business Model dermaPACE device Future Business Model Portfolio of value-added wound care solutions encompassing dermaPAC
Slide 15: Global Clinical Studies
Global Clinical Studies Action Sites Ql Q2 Pharmacoeconomic - FollowOn1 12 - Follow On2 8 New AWC - VLU 18 - Pressure Ulcer 18 - ALU 18 - Burn 2 Mechanism of Action - Dr. Siemionow 1 Vascularization/Perfusion - Dr. Alvarez +2 3 - Global 5 Surgical Incisions/Cosmetic - Dr. Galliano (Protocol) 1 - Dr.
Slide 16: Action
Action KOVE (South Korea) - Dr.Han DFU - 3 Universities Scar Ortho Medica (Benelux) - DFU @Home Italy - Dr. Casino VLU Australia - Dr. Miller VLU Brazil - Dr. Bruna DFU - Dr. Bruna VLU Unrestricted Grants (Adjunctive) - Dr. Galliano - Dr. Ryzellman - Uof Miami Additional Global Posters and Papers 20
Slide 17: Intellectual Property (IP) Organic Growth
Intellectual Property (IP) Organic Growth Number of Patents in 2006, 2012, and 2017 2006 2012 2017 UsPatents | 14 18 27 Fe sitet 10 9 18 Patents UsAppl(s) [11 9 15 Foreign a i. 2 10 6 i Appl(s) TOTAL 37 46 66 50 24% 44% | 2012 Percentage 78% | 2006 40 Wound care si Ononeaes TOTAL Wound care ve 30 :
Slide 18: Device Sales — Historical and 2017 Projection
Device Sales — Historical and 2017 Projection 70 Epoaul | 2012 2013 2014 2015 2016 2017 - Projection MdermaPACE —-MorthoPACE
Slide 19: Non-Medical Markets
Non-Medical Markets Addressable Opportunities Covered by Patents Energy Production Water = Advanced Fracking = Fracking Water Cleaning = Improved / Enhanced Oil = Industrial Water Cleaning Extraction Recovery = Drinking Water Cleaning Food Industry Industrial Biofilms = Preservation ® Biofilm Destru
Slide 20: Peer Company Market Caps
Company Name Ticker Symbol Market Cap (as of 02/09/18) Integra Life Sciences Holding Corp. NASDAQ: IART $3.9B MiMedx Group Inc. NASDAQ: MDXG $1.7B Osiris Therapeutics Inc. OTC MKTS: OSIR $254.83MM SANUWAVE Health, Inc. OTC MKTS: SNWV $27.9MM Derma Sciences Inc. (NASDAQ: DCS!) was acquired by Integra
Slide 21: Select Financial Information
Select Financial Information Cash and Cash Equivalents - Dec. 31, 2017 $1.8M Common Shares Outstanding 138.8M Warrants 76.1M Options 16.2M Notes Payable - Due January 31, 2018 $5.4M (1) (1) Due to HealthTronics, Inc. as part of original 2005 purchase price 21
Slide 22: Management Team
Management Team Kevin Richardson II, Chairman of the Board — Joined August 2005 = Joined the Company as chairman of the board of directors in August of 2005. Brings a broad array of financial knowledge for healthcare information technology, financial services, business services and other industries.
Slide 23: SANUWAVE: Healing today. Curing tomorrow.
SANUVAVE Healing today. Curing tomorrow. OTCQB: SNWV SANUWAVE Health, Inc. 3360 Martin Farm Road, Suite 100 Suwanee, GA 30024 info@sanuwave.com +1(770) 419-7525
SANUWAVE Health — Investor Presentation (February 2018) on 6ix